Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

To evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of the humanised antiepidermal growth factor receptor monoclonal antibody matuzumab combined with epirubicin, cisplatin and capecitabine (ECX) in patients as first-line treatment for advanced oesophagogastric cance...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Rao, S, Starling, N, Cunningham, D, Benson, M, Wotherspoon, A, Lüpfert, C, Kurek, R, Oates, J, Baselga, J, Hill, A
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2008
Teme:
Clinical Study
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2538760/
https://ncbi.nlm.nih.gov/pubmed/19238629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604622
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki